Quantcast

Latest Anthracyclines Stories

2009-06-08 00:30:00

Overview of 11 peer review publications presented in 'Future Oncology' SEATTLE, June 8 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) reports a summary of peer reviewed publications spanning preclinical, Phase I and Phase II clinical studies with pixantrone was reviewed in the May 2009 edition of Future Oncology (Volume 5, Issue 4) which is now available on line. The article, "Pixantrone: a promising drug in the treatment of non-Hodgkin lymphomas," was...

2009-06-01 13:00:00

First Randomized Trial to Demonstrate Superior Clinical Benefit in Relapsed/Refractory Aggressive NHL ORLANDO, Fla., June 1 /PRNewswire-FirstCall/ -- Intent to treat Analysis results per FDA agreed upon Statistical Analysis Plan Significant Increase in Complete Remission Rates 20% vs. 5.7%; p=0.021 Significant Increase in Overall Response Rate 37.1% vs. 14.3%; p=0.003 Significant increase in percent of all patients whose response lasted greater than or equal to four months 25.7% vs....

2009-05-28 16:01:00

HORSHAM, Pa., May 28 /PRNewswire/ -- Centocor Ortho Biotech Products, L.P. today announced that data related to several compounds will be presented at the 45th American Society of Clinical Oncology (ASCO) Annual Meeting in Orlando, Fla., from May 29 to June 2, 2009. The studies were sponsored by Centocor Ortho Biotech Products, L.P. or its research partner, Ortho Biotech Oncology Research and Development, a unit of Johnson & Johnson Pharmaceutical Research & Development, L.L.C. "We...

2009-05-21 15:05:00

PALO ALTO, Calif., May 21 /PRNewswire-FirstCall/ -- Telik, Inc. (Nasdaq: TELK) announced today that the results from the randomized clinical study of canfosfamide (TELCYTA(R), TLK286) in combination with pegylated liposomal doxorubicin (PLD) vs. PLD will be presented at the 45th annual meeting of the American Society of Clinical Oncology (ASCO) which will be held from May 29 to June 2 in Orlando, FL. Details of the presentation are as follows: -- Abstract #5552 - General Poster...

2009-05-19 10:00:00

Updated Safety data presented at BIO International Convention in Atlanta ATLANTA, May 19 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) released updated safety data today from its pixantrone phase III 301 EXTEND trial demonstrating the effectiveness of pixantrone in patients with relapsed/refractory aggressive non-Hodgkin's lymphoma (NHL) for whom anthracycline-related drugs are typically not to be used due to the increased risk of cardiac failure. As noted...

2009-05-13 07:00:00

PRINCETON, N.J., May 13 /PRNewswire/ -- Celator Pharmaceuticals today announced that Scott Jackson, chief executive officer, is scheduled to present at the 2009 BIO International Convention in Atlanta. Mr. Jackson will provide a corporate overview and an update on the company's progress with two ongoing Phase 2 clinical trials of CPX-351 in newly diagnosed acute myeloid leukemia (AML) patients and first-relapse AML patients. The presentation will be held on Wednesday, May 20, 2009 at 3:40pm...

2009-04-22 07:00:00

PRINCETON, N.J., April 22 /PRNewswire/ -- Celator Pharmaceuticals today announced that new data from animal studies of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in consolidation treatment for leukemia and of CPX-1 (Irinotecan HCl:Floxuridine) Liposome Injection in combination with biological agents for the treatment of colorectal cancer were presented at the 100th Annual Meeting of the American Association for Cancer Research (AACR) in Denver, Colorado (Abstracts 4568 and 4578)....

2009-03-31 11:05:59

Caltech researcher helps develop technique that homes in on aggressive, difficult-to-treat HER2+ breast cancer cellsCombining a compound known as a gallium corrole with a protein carrier results in a targeted cancer therapy that is able to detect and eliminate tumors in mice with seemingly fewer side effects than other breast-cancer treatments, says a team of researchers from the California Institute of Technology (Caltech), the Israel Institute of Technology (Technion) and the Cedars-Sinai...

2009-03-18 06:00:00

PRINCETON, N.J., March 18 /PRNewswire/ -- Sopherion Therapeutics, LLC, a biopharmaceutical company focused on the development and commercialization of anti-cancer therapies, announced that it completed enrollment in its pivotal Phase III study of nonpegylated liposomal doxorubicin (Myocet(TM)) in metastatic HER-2-overexpressing breast cancer. This is a pivotal Phase III trial of Sopherion's lead product in combination with the current standard of care, paclitaxel (Taxol) and trastuzumab...

2009-02-06 09:09:41

Scientists including one from The University of Texas Health Science Center at Houston successfully predicted the outcome of a nano drug on breast tumors in a pre-clinical study. Their research could help determine which patients will respond best to cancer-fighting nano drugs.Researchers from the Georgia Institute of Technology and Emory University also participated in the study, which appears in the February issue of Radiology.The investigators used contrast agents encapsulated in tiny fat...


Word of the Day
pungle
  • To take pains; labor assiduously with little progress.
This word comes from the Spanish 'pongale,' put it.
Related